NCT03964337View on ClinicalTrials.gov

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
Prostate CancerProstate Cancer AdenocarcinomaNon-Metastatic
Interventions
DRUG

Cabozantinib

Cabozantinib 40 mg by mouth daily for 4 weeks.

PROCEDURE

Radical Prostatectomy

Radical prostatectomy as part of routine medical care.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Duke University

OTHER